• Eaton Scientific Systems Ltd., of Beverly Hills, Calif., a wholly owned subsidiary of Pristine Solutions Inc., said it completed the protocol for the Phase I/II study of Tropine 3, its version of homatropine in oral suspension, for women afflicted with hot flashes during pre-menopause, perimenopause and postmenopause. Read More
• Janssen Research & Development LLC, of Raritan, N.J, a unit of Johnson & Johnson, said it submitted a complete response to the FDA for the use of anticoagulant Xarelto (rivaroxaban) to reduce the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS), and also resubmitted its supplemental new drug application for Xarelto to reduce the risk of stent thrombosis in patients with ACS. Read More
• Imprimis Pharmaceuticals Inc., of Solana Beach, Calif., inked a strategic development and investment agreement with Professional Compounding Centers of America Inc. (PCCA), of Houston, which also made a $4 million equity investment through a private transaction. Read More
Newly launched Canadian biotech Fedora Pharmaceuticals Inc. has landed in the antibiotics space with multiple beta-lactamase inhibitor candidates in the lead optimization stage of preclinical development and investigational new drug-enabling studies expected to begin next year. Read More
Debt financing of up to $15 million, plus a Series E preferred stock financing closed in the second quarter, will help KaloBios Pharmaceuticals Inc., of South San Francisco, advance its monoclonal antibody therapeutics through Phase II trials in asthma and cystic fibrosis, as well as fund a Phase I trial in cancer. Read More
The looming spending sequestration, scheduled to take effect Jan. 2, has left a big question mark hanging over activities at the FDA, National Institutes of Health (NIH) and other federal agencies. Read More
With two key value inflection points approaching, Biotie Therapies Oy did some advance corporate housekeeping by adding €30 million (US$38.3 million) to its coffers, to strengthen its position for any upcoming licensing negotiations. Read More
Researchers at Washington University in St. Louis discovered a relationship between amyloid-beta (A-beta) levels and sleep patterns that might find use as an early diagnostic marker of Alzheimer's disease. Read More
